"Dallas Nephrology Associates (DNA) is a national leader in providing comprehensive care for patients with kidney disease, kidney transplant, and hypertension."

During the past decade, Renal Disease Research Institute conducted 20 clinical trials. In the 10-year time frame, 20 clinical trials started and 3 clinical trials were completed, i.e. on average, 15% percent of trials that started reached the finish line to date. In the past 5 years, 12 clinical trials started and 3 clinical trials were completed. i.e. 25% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Renal Disease Research Institute" #1 sponsor was "Reata Pharmaceuticals, Inc." with 5 trials, followed by "Allena Pharmaceuticals" with 2 trials sponsored, "Chiesi Farmaceutici S.p.A." with 2 trials sponsored, "Amicus Therapeutics" with 1 trials sponsored and "Boehringer Ingelheim" with 1 trials sponsored. Other sponsors include 4 different institutions and companies that sponsored additional 14 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Renal Disease Research Institute" #1 collaborator was "Eli Lilly and Company" with 1 trials as a collaborator, "ICON Clinical Research" with 1 trials as a collaborator and "Medical Research Council Population Health Research Unit, CTSU, University of Oxford (academic lead)" with 1 trials as a collaborator. Other collaborators include -3 different institutions and companies that were collaborators in the rest 3 trials.

According to Clinical.Site data, the most researched conditions in "Renal Disease Research Institute" are "Fabry Disease" (5 trials), "Alport Syndrome" (3 trials), "Autosomal Dominant Polycystic Kidney" (3 trials), "Focal Segmental Glomerulosclerosis" (3 trials) and "Chronic Kidney Diseases" (2 trials). Many other conditions were trialed in "Renal Disease Research Institute" in a lesser frequency.

Most popular intervention types in "Renal Disease Research Institute" are "Drug" (18 trials), "Biological" (2 trials), "Other" (2 trials) and "Device" (1 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (4 trials), "Bardoxolone methyl oral capsule" (2 trials), "Placebo oral capsule" (2 trials), "pegunigalsidase alfa" (2 trials) and "ALLN-177" (1 trials). Other intervention names were less common.

The vast majority of trials in "Renal Disease Research Institute" are 20 trials for "All" genders.

Currently, there are NaN active trials in "Renal Disease Research Institute". undefined are not yet recruiting, 6 are recruiting, 4 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 8 completed trials in Renal Disease Research Institute, undefined suspended trials, and 2 terminated clinical trials to date.

Out of the total trials that were conducted in Renal Disease Research Institute, 0 "Phase 1" clinical trials were conducted, 8 "Phase 2" clinical trials and 12 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 1 trials that are defined as “Not Applicable".